Overview
Built for long-lasting performance
The Astra™ MRI SureScan™ pacemaker is built keeping long-lasting performance in mind and comes equipped with a hardware architecture that optimizes circuitry to reduce current drain and improve longevity.1,2
- Dual-chamber — 15.3 years*
Features
Reduce the progression to permanent atrial fibrillation (AF) with reactive atrial antitachycardia pacing (ATP) algorithm.
In the MINERVA trial,3 reactive ATP algorithm demonstrates:
- 61% relative reduction for the progression to permanent AF
- 42% relative reduction in AF-related hospitalizations and 68% relative reduction in emergency room visits4
- 45% relative reduction for AF cardioversions5
Reduce unnecessary right ventricular (RV) pacing with updated managed ventricular pacing (MVP™) algorithm2
Now with the option to control maximum atrioventricular (AV) interval:
- MVP™ algorithm reduces unnecessary RV pacing by 99%.6
- RV pacing is associated with a 1% increase in risk of atrial fibrillation (AF) for each 1% increase in RV pacing.7
- RV pacing is also associated with an increased risk of heart failure (HF) hospitalization.7
Expanded MRI access
The Astra™ MRI SureScan™ pacemaker is approved for safe use in the MR environment, when MR conditions for use are met. With the Astra™ MRI pacemaker, patients have access to 1.5T and 3T full body scanning.
- Our SureScan™ devices and leads work in any combination.
- Scanning conditions are simple: no MRI exclusion zone, no patient height restriction, and no MRI duration restrictions.
Ordering information
| Item number | Description |
|---|---|
|
X2DR01 |
Astra™ XT DR MRI SureScan™ dual-chamber pacemaker |
Educational resources on Medtronic Academy
Access interactive courses, videos, and educational resources to extend your knowledge.
*
DR: MVP™, SR: VVI 50%, 500 ohm, 2.5V, pre-storage EGM off.
1
Medtronic, Advisa DR MRI™ SureScan™ A3DR01, clinician manual, M927882A001C, 2009–07–23.
2
Medtronic, Astra™ XT DR MRI SureScan™ X2DR01, device manual, M964366A001 B, 2016–10–22. Medtronic, Astra™ XT SR MRI SureScan™ X2SR01, device manual, M964368A001 B, 2016–10–20.
3
Boriani G, Tukkie R, Manolis AS, et al. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. Eur Heart J. 2014;35(35):2352–62.
4
Boriani G, Manolis AS, Tukkie R, et al. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: an analysis of the randomized MINERVA trial. Heart Rhythm. 2015;12(6):1192–200.
5
European Heart Journal. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. Published September 14, 2014; volume 35, issue 35; 2352–2362.
6
Gillis AM, Pürerfellner H, Israel CW. Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. Pacing Clin Electrophysiol. 2006;29(7):697–705.
7
Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107(23):2932–2937.